Subretinal rAAV2-based VEGF-Trap gene therapy for neovascular age-related macular degeneration: Preclinical assessment and phase 1 trial results.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 42285094.
- Also identified by DOI 10.1016/j.xcrm.2026.102869.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Intraocular vascular endothelial growth factor (VEGF) antagonists for neovascular age-related macular degeneration (nAMD) require frequent injections, leading to treatment burden and suboptimal outcomes. LX102 is an rAAV2-based gene therapy encoding VEGF-Trap via subretinal delivery. In laser-induced choroidal neovascularization (CNV) mouse models, LX102 prevents lesion formation and progression in a dose-dependent manner. In non-human primates, a single LX102 injection reduces grade IV CNV lesions by over 85% and maintains transgene expression for 26 weeks without drug-related ocular abnormalities. In a phase 1 dose-escalation study, 12 participants with nAMD receive a single LX102 administration (2 × 10<sup>10</sup> to 1.25 × 10<sup>11</sup> vector genomes/eye). LX102 is well tolerated with no clinically significant inflammation. Eleven participants (91.7%) require no supplemental anti-VEGF injections through 1 year, with stable visual acuity and reduced central subfield thickness in most cases. These findings support LX102 as a potential sustained therapeutic approach for nAMD. This study was registered at chinadrugtrials.org.cn (CTR20230194) and ClinicalTrials.gov (NCT06198413).